Table 6.

Mortality

	Valid	No.	Alive		Dead		P value
			Number	%	Number	%
Patients			100	90.12	11	9.9
Male gender	111	47	38	38.03	9	81.8	0.005
Ambulatory	104	75	74	77.93	1	10.0	0.000
CDI risk factors
Prior hospitalization	111	80	69	69.03	11	100.0	0.030
Antibiotics use	108	89	81	82.73	8	80.0	0.834
PPI usage	110	37	31	31.33	6	54.5	0.122
Chemotherapy	111	19	19	19.03	0	0.0	0.112
IBD	111	20	20	20.03	0	0.0	0.101
Steroid usage	111	17	16	16.03	1	9.1	0.546
Fever	76	21	15	23.13	6	54.5	0.031
Severe	110	20	13	13.03	7	63.6	0.000
Adverse events	107	19	15	15.53	4	40.0	0.053
Route
Lower GI	111	50	44	44.03	6	54.5	0.023
Upper GI1		24	19	19.03	5	45.5
Capsules		37	37	37.03	0	0.0
0-1 previous CDI	107	24	19	19.83	5	45.5	0.053
2+ previous CDI		83	77		6
Indication	111						0.306
Refractory		23	19	19.03	4	36.4
Recurrent		82	76	76.03	6	54.5
Prior therapy
Metronidazole	110	89	80	80.83	9	81.8	0.936
Vancomycin	110	109	98	99.03	11	100.0	0.738
Combination	109	31	25	25.53	6	54.5	0.043
Outcomes
Adverse events	107	19	15	15.53	4	40.0	0.053
Response to FMT	111	94	88	88.03	6	54.5	0.003
			Mean	SD	Mean	SD	Sigma
Age (yr)	111		62.37	21.656	84	5.797	0.000
Charlson comorbidity score	81		4.57	2.98	8	2.4	0.001
Previous CDI episodes (n)	107		2.57	1.633	1.45	1.368	0.025
Time from 1st CDI (d)	89		138.47	197.991	110.75	63.036	0.493
Creatinine (mg/dL)	76		1.44	1.507	1.74	1.193	0.482
Albumin (mg/L)	54		3.34	0.782	2.4	0.408	0.010
WBC (103/dL)	76		13.65	18.87	15.64	78.62	0.564

¹Upper GI: Gastroscopy, nasogastric tube or through percutaneous endoscopic gastrostomy;

²Percentages refer to the total number of subjects in the cohort;

³Percentages refer to the number of subjects in the specific group. CDI: Clostridium difficile infection; IBD: Inflammatory bowel diseases; PPI: Proton pump inhibitor; GI: Gastrointestinal; FMT: Fecal microbiota implantation; IQR: Inter quartile range; WBC: White blood cells; Prior hospitalization: Hospitalization within the 3 mo prior to the FMT; Prior hospitalization: Antibiotics use in the 3 mo prior to the FMT.